No photo of Edward L. Schwartz

View Scopus Profile

Edward L. Schwartz, Ph.D.

  • 4269 Citations
  • 31 h-Index
1977 …2024

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Edward L. Schwartz is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Vulnerability of SCLC based on bi-allelic genetic inactivation of RB1 and TP53

Schwartz, E. L.

National Institutes of Health

4/12/19 → 3/31/24

Project: Research project

    • Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis

    Zhu, L. & Schwartz, E. L.

    National Institutes of Health

    6/3/16 → 5/31/21

    Project: Research project

    • Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis

    Schwartz, E. L.

    National Institutes of Health

    7/9/12 → 5/31/18

    Project: Research project

    • Anti-angiogenic actions of taxotere

    Schwartz, E. L.

    National Institutes of Health

    9/29/03 → 6/30/09

    Project: Research project

    • Mechanisms of thymidine phosphorylase angiogenesis

    Schwartz, E. L.

    National Institutes of Health

    12/1/00 → 4/30/12

    Project: Research project

    • Publications

    • 4269 Citations
    • 31 h-Index
    • 82 Article
    • 5 Review article
    • 2 Letter

    Lysosome membrane permeabilization and disruption of the molecular target of rapamycin (mTOR)-lysosome interaction are associated with the inhibition of lung cancer cell proliferation by a chloroquinoline analog

    Sironi, J., Aranda, E., Nordstrøm, L. U. & Schwartz, E. L., Jan 2019, In : Molecular Pharmacology. 95, 1, p. 127-138 12 p.

    Research output: Contribution to journal › Article

    • 1 Scopus citations

    Discovery of autophagy inhibitors with antiproliferative activity in lung and pancreatic cancer cells

    Nordstrøm, L. U., Sironi, J., Aranda, E., Maisonet, J., Perez-Soler, R., Wu, P. & Schwartz, E. L., Feb 12 2015, In : ACS Medicinal Chemistry Letters. 6, 2, p. 134-139 6 p.

    Research output: Contribution to journal › Article

    • 14 Scopus citations

    RICTOR amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mTORC1/2 inhibitors

    Cheng, H., Zou, Y., Ross, J. S., Wang, K., Liu, X., Halmos, B., Ali, S. M., Liu, H., Verma, A., Montagna, C., Chachoua, A., Goel, S., Schwartz, E. L., Zhu, C., Shan, J., Yu, Y., Gritsman, K., Yelensky, R., Lipson, D., Otto, G. & 5 others, Hawryluk, M., Stephens, P. J., Miller, V. A., Piperdi, B. & Perez-Soler, R., Dec 2015, In : Cancer discovery. 5, 12, p. 1262-1270 9 p.

    Research output: Contribution to journal › Article

    • 46 Scopus citations

    Stilbene 5c, a microtubule poison with vascular disrupting properties that induces multiple modes of growth arrest and cell death

    Alotaibi, M. R., Asnake, B., Di, X., Beckman, M. J., Durrant, D., Simoni, D., Baruchello, R., Lee, R. M., Schwartz, E. L. & Gewirtz, D. A., Nov 12 2013, In : Biochemical Pharmacology. 86, 12, p. 1688-1698 11 p.

    Research output: Contribution to journal › Article

    • 6 Scopus citations

    The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib

    Zou, Y., Ling, Y. H., Sironi, J., Schwartz, E. L., Perez-Soler, R. & Piperdi, B., Jun 2013, In : Journal of Thoracic Oncology. 8, 6, p. 693-702 10 p.

    Research output: Contribution to journal › Article

    • 74 Scopus citations